Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

Peer Review reports

Original Submission
27 Oct 2017	Submitted	Original manuscript
2 Nov 2017	Author responded	Author comments - Satoshi Ikeda
Resubmission - Version 2
2 Nov 2017	Submitted	Manuscript version 2
7 Nov 2017	Author responded	Author comments - Satoshi Ikeda
Resubmission - Version 3
7 Nov 2017	Submitted	Manuscript version 3
22 Nov 2017	Reviewed	Reviewer Report - Chi-Lu Chiang
4 Dec 2017	Reviewed	Reviewer Report - Ryo Morita
27 Dec 2017	Author responded	Author comments - Satoshi Ikeda
Resubmission - Version 4
27 Dec 2017	Submitted	Manuscript version 4
22 Jan 2018	Author responded	Author comments - Satoshi Ikeda
Resubmission - Version 5
22 Jan 2018	Submitted	Manuscript version 5
12 Feb 2018	Author responded	Author comments - Satoshi Ikeda
Resubmission - Version 6
12 Feb 2018	Submitted	Manuscript version 6
Publishing
19 Feb 2018	Editorially accepted
2 Mar 2018	Article published	10.1186/s12885-018-4150-y

Back to article page